Wigen biomedicine technology (Shanghai) Co., Ltd. was established in April 2018 and is a new type of pharmaceutical enterprise dedicated to innovative drug development. The company’s main founders have held important positions in R&D and management in a number of large and well-known pharmaceutical companies at home and abroad.
Yuli Xie is co-founder and also serves as the general manager of Wigen. Before Wigen, he held several positions in several pharmaceutical companies in US and China, including project leader in Columbia-Merck joint incubator lab, director of Shanghai R&D center of Yangtze River Pharmaceutical group, associate director of Shanghai R&D center of Otsuka, director of CMC office at WuXi AppTec, and operation head of PDS at WuXi AppTec. He has been responsible for operation, project selection, project management and market research. In his career, he published over 30 academic papers and held 5 international and 3 Chinese patents. He has over 15 year experience in innovative and generic drug development and is familiar with therapeutic area and new targets, and regulation, policy and market.
The company’s R&D center is located in Shanghai’s Zhangjiang Pharmaceutical Valley. The company’s management team has a PhD background and a world-class new drug research and development team, and the company’s sustainable development is focused on chemistry and innovation, biotechnology and the future, focusing on the development of small molecule anti-cancer drugs for these targets and innovative technologies to facilitate drug development. Explore, develop and deliver innovative products and services that save lives and improve lives around the world.